warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
Eli Lilly I5B-MC-JGDN: A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin in Pediatric Patients with Advanced or Metastatic Cancer
Brief Description  
The primary objective of this study is to determine a safe dose of olaratumab alone or in combination with chemotherapy regimens that can be administered to pediatric patients.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Soft Tissue
Status  
OPEN
Start Date  
03/01/2017
IRB Number  
00018380
Principal Investigator  
Jacobsen, Chad Thomas
Contact Name  
Gerri Robinson

For More Information, Contact  Gerri  , Robinson
Phone:  980-442-2355 Fax:    
Email:  gerri.robinson@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close